FindTrial
Sign In

A self-control study for the changes of the composition of gut microbiota and the degree of small intestinal mucosal injury in patients taking enteric-coated aspirin before and after the treatment of lactobacillus for 2 months

A self-control study for the changes of the composition of gut microbiota and the degree of small intestinal mucosal injury in patients taking enteric-coated aspirin before and after the treatment of lactobacillus for 2 months

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023132
Enrollment
Unknown
Registered
2019-05-13
Start date
2019-05-15
Completion date
Unknown
Last updated
2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aspirin related small intestinal mucosal injury

Interventions

Lactobacillus group:Lactobacillus complex capsules
Control group:No

Sponsors

Beijing Anzhen Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients with small intestinal mucosal injury caused by primary and secondary prevention of cardiovascular and cerebrovascular diseases taking enteric-coated aspirin; (2) Agreeing with the research plan; and (3) Signing informed consent voluntarily.

Exclusion criteria

Exclusion criteria: (1) Contraindications for Magnetically Controlled Capsule Endoscopy, including cardiac pacemaker, cochlear implantation, magnetic metal drug perfusion pump, electronic devices such as nerve stimulators and magnetic metal foreign bodies; (2) Suspected or known gastrointestinal obstruction, stenosis, fistula or diverticulum, pregnant women, previous digestive tract surgery or surgical history leading to changes in abdominal digestive tract structure, no surgical conditions or refusal to undergo any abdominal surgery (as once the capsule retension in vivo, it may need to be removed by operation); (3) Taking related drugs that have had an impact on the experiment in the past 1 month, including a. Antibiotics, b. Probiotics, c. A variety of drugs that inhibit the secretion of gastric acid, d. Cytokines, immunosuppressants and cytotoxicity, e. Hormones, f. Other drugs affecting gut microbiota; (4) Taking other antiplatelet drugs or anticoagulant drugs at the same time; (5) Patients diagnosed as gastrointestinal tumors or inflammatory bowel diseases by Magnetically Controlled Capsule Endoscopy; (6) allergic to aspirin, lactobacillus complex capsule, polyethylene glycol electrolyte dispersion and polymer materials.

Design outcomes

Primary

MeasureTime frame
Gut microbiota;Inflammatory cytokines;Small intestinal mucosal injury;—

Countries

China

Contacts

Public ContactZhang Jie

Beijing Anzhen Hospital, Capital Medical University

zhangjie4155@sina.com+86 13601337670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026